科拓生物
(300858)
| 流通市值：36.14亿 | | | 总市值：49.14亿 |
| 流通股本：1.94亿 | | | 总股本：2.63亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 163,345,625.11 | 77,612,862.67 | 302,793,277.36 | 218,714,979.06 |
| 营业收入 | 163,345,625.11 | 77,612,862.67 | 302,793,277.36 | 218,714,979.06 |
| 二、营业总成本 | 119,905,813.02 | 56,526,026.1 | 211,440,159.85 | 152,721,092.56 |
| 营业成本 | 82,916,596.7 | 38,548,876.48 | 126,410,969.06 | 100,297,002.12 |
| 税金及附加 | 2,320,854.35 | 612,186.92 | 5,274,382.5 | 2,931,032.24 |
| 销售费用 | 13,832,941.7 | 7,268,846.55 | 36,507,476.96 | 24,751,458.36 |
| 管理费用 | 14,050,358.7 | 7,195,697.6 | 31,395,566.37 | 20,497,814.45 |
| 研发费用 | 16,738,749.21 | 7,884,151.19 | 36,327,014.28 | 24,045,152.14 |
| 财务费用 | -9,953,687.64 | -4,983,732.64 | -24,475,249.32 | -19,801,366.75 |
| 其中:利息费用 | 140,603.95 | 139,586.82 | 251,040.48 | 239,872.31 |
| 其中:利息收入 | 10,108,533.51 | 5,130,122.38 | 24,757,594.36 | 20,064,354.11 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 956,219.16 | 316,957.27 | 2,013,454.04 | 1,486,574.28 |
| 加:投资收益 | 1,298,927.79 | 982,169.09 | 3,577,981.47 | 1,854,709.79 |
| 资产处置收益 | - | - | 652,262.64 | 566,011.33 |
| 信用减值损失(新) | -377,431.9 | 157,529.93 | 3,193,285.57 | 1,943,339.88 |
| 其他收益 | 4,554,818.53 | 2,789,709.85 | 8,672,581.21 | 7,938,974.89 |
| 四、营业利润 | 49,872,345.67 | 25,333,202.71 | 109,462,682.44 | 79,783,496.67 |
| 加:营业外收入 | 23,012.44 | 23,011.47 | 58,229.03 | 76,067.77 |
| 减:营业外支出 | 13,697.65 | 0 | 692,974.62 | 176,598.86 |
| 五、利润总额 | 49,881,660.46 | 25,356,214.18 | 108,827,936.85 | 79,682,965.58 |
| 减:所得税费用 | 8,676,597.42 | 5,026,589.55 | 14,471,856.39 | 8,492,040.88 |
| 六、净利润 | 41,205,063.04 | 20,329,624.63 | 94,356,080.46 | 71,190,924.7 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 41,205,063.04 | 20,329,624.63 | 94,356,080.46 | 71,190,924.7 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 41,205,063.04 | 20,329,624.63 | 94,356,080.46 | 71,190,924.7 |
| 扣除非经常损益后的净利润 | 35,126,939.95 | 16,664,806.63 | 82,282,318.04 | 61,097,922.67 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.16 | 0.08 | 0.36 | 0.27 |
| (二)稀释每股收益 | 0.16 | 0.08 | 0.36 | 0.27 |
| 八、其他综合收益 | 9.89 | -0.85 | 31.32 | - |
| 归属于母公司股东的其他综合收益 | 9.89 | -0.85 | 31.32 | - |
| 九、综合收益总额 | 41,205,072.93 | 20,329,623.78 | 94,356,111.78 | 71,190,924.7 |
| 归属于母公司股东的综合收益总额 | 41,205,072.93 | 20,329,623.78 | 94,356,111.78 | 71,190,924.7 |
| 公告日期 | 2025-08-20 | 2025-04-23 | 2025-04-23 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |